Stephen J. Bagley

Dec 9, 2024 | cell.com | Meghan T. Logun |Xin Wang |Yusha Sun |Stephen J. Bagley |Nannan Li |Arati Desai | +9 more

Keywordsglioblastomapatient-derived tumor organoidex vivoCAR-T cell therapyreal-time correlativeclinical trialorganoidcytokineGet full text accessLog in, subscribe or purchase for full access. References1. Drost, J. ∙ Clevers, H. Organoids in cancer researchNat. Rev. Cancer. 2018; 18:407-4182. Jiang, X. ∙ Oyang, L. ∙ Peng, Q. ... Organoids: opportunities and challenges of cancer therapyFront. Cell Dev. Biol. 2023; 11, 12325283. Wang, X. ∙ Sun, Y. ∙ Zhang, D.Y. ...

Oct 4, 2024 | biorxiv.org | Meghan T. Logun |Xin Wang |Yusha Sun |Stephen J. Bagley

AbstractPatient-derived tumor organoids have been leveraged for disease modeling and preclinical studies, but rarely applied in real-time to aid with interpretation of patient treatment responses in clinics. We recently demonstrated early efficacy signals in a first-in-human, phase 1 study of dual-targeting chimeric antigen receptor T cells (EGFR-IL13Rα2 CAR-T cells) in patients with recurrent glioblastoma.

Mar 27, 2024 | healio.com | Josh Friedman |Mindy Valcarcel |Stephen J. Bagley

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Novel CAR-T targeting both EGFR and IL13Ra2 reduced tumor sizes within 48 hours in patients with glioblastoma. No grade 4 or 5 neurotoxicity occurred during the study.

Mar 21, 2024 | onclive.com | Stephen J. Bagley

March 21, 2024Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas. Welcome to OncLive On Air®! I’m your host today, Caroline Seymour. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.

Mar 13, 2024 | nature.com | Stephen J. Bagley |Meghan T. Logun |Julie K. Jadlowsky |Fang Chen |MacLean P. Nasrallah |Wei-Ting Hwang | +5 more

AbstractRecurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study’s primary endpoints were safety and determination of the maximum tolerated dose.